Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy

Rifaximin (RFX) treatment can attenuate not only hyperammonemia but also Enterococcus faecalis translocation and 10‐7G values, suggesting that RFX treatment may improve intestinal inflammation and result in better overall survival.[Image: see text]

Detalles Bibliográficos
Autores principales: Tamai, Yasuyuki, Iwasa, Motoh, Eguchi, Akiko, Shigefuku, Ryuta, Kamada, Yoshihiro, Miyoshi, Eiji, Takei, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264230/
https://www.ncbi.nlm.nih.gov/pubmed/34263080
http://dx.doi.org/10.1002/jgh3.12596
_version_ 1783719507136610304
author Tamai, Yasuyuki
Iwasa, Motoh
Eguchi, Akiko
Shigefuku, Ryuta
Kamada, Yoshihiro
Miyoshi, Eiji
Takei, Yoshiyuki
author_facet Tamai, Yasuyuki
Iwasa, Motoh
Eguchi, Akiko
Shigefuku, Ryuta
Kamada, Yoshihiro
Miyoshi, Eiji
Takei, Yoshiyuki
author_sort Tamai, Yasuyuki
collection PubMed
description Rifaximin (RFX) treatment can attenuate not only hyperammonemia but also Enterococcus faecalis translocation and 10‐7G values, suggesting that RFX treatment may improve intestinal inflammation and result in better overall survival.[Image: see text]
format Online
Article
Text
id pubmed-8264230
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-82642302021-07-13 Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy Tamai, Yasuyuki Iwasa, Motoh Eguchi, Akiko Shigefuku, Ryuta Kamada, Yoshihiro Miyoshi, Eiji Takei, Yoshiyuki JGH Open Brief Reports Rifaximin (RFX) treatment can attenuate not only hyperammonemia but also Enterococcus faecalis translocation and 10‐7G values, suggesting that RFX treatment may improve intestinal inflammation and result in better overall survival.[Image: see text] Wiley Publishing Asia Pty Ltd 2021-06-23 /pmc/articles/PMC8264230/ /pubmed/34263080 http://dx.doi.org/10.1002/jgh3.12596 Text en © 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Reports
Tamai, Yasuyuki
Iwasa, Motoh
Eguchi, Akiko
Shigefuku, Ryuta
Kamada, Yoshihiro
Miyoshi, Eiji
Takei, Yoshiyuki
Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
title Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
title_full Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
title_fullStr Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
title_full_unstemmed Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
title_short Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
title_sort rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264230/
https://www.ncbi.nlm.nih.gov/pubmed/34263080
http://dx.doi.org/10.1002/jgh3.12596
work_keys_str_mv AT tamaiyasuyuki rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy
AT iwasamotoh rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy
AT eguchiakiko rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy
AT shigefukuryuta rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy
AT kamadayoshihiro rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy
AT miyoshieiji rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy
AT takeiyoshiyuki rifaximinamelioratesintestinalinflammationincirrhoticpatientswithhepaticencephalopathy

Ejemplares similares